It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
In February and March 2020, two mass swab testing campaigns were conducted in Vo’, Italy. In May 2020, we tested 86% of the Vo’ population with three immuno-assays detecting antibodies against the spike and nucleocapsid antigens, a neutralisation assay and Polymerase Chain Reaction (PCR). Subjects testing positive to PCR in February/March or a serological assay in May were tested again in November. Here we report on the results of the analysis of the May and November surveys. We estimate a seroprevalence of 3.5% (95% Credible Interval (CrI): 2.8–4.3%) in May. In November, 98.8% (95% Confidence Interval (CI): 93.7–100.0%) of sera which tested positive in May still reacted against at least one antigen; 18.6% (95% CI: 11.0–28.5%) showed an increase of antibody or neutralisation reactivity from May. Analysis of the serostatus of the members of 1,118 households indicates a 26.0% (95% CrI: 17.2–36.9%) Susceptible-Infectious Transmission Probability. Contact tracing had limited impact on epidemic suppression.
Vo’, Italy, is a unique setting for studying SARS-CoV-2 antibody dynamics because mass testing was conducted there early in the pandemic. Here, the authors perform two follow-up serological surveys and estimate seroprevalence, the extent of within-household transmission, and the impact of contact tracing.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
; Lavezzo Enrico 2
; Manuto Laura 2 ; Ciavarella Constanze 1
; Pacenti Monia 3 ; Boldrin Caterina 3 ; Cattai Margherita 3 ; Saluzzo Francesca 2
; Franchin Elisa 2 ; Del Vecchio Claudia 2 ; Caldart Federico 2
; Castelli Gioele 2
; Nicoletti, Michele 2
; Nieddu Eleonora 2 ; Salvadoretti Elisa 2 ; Labella Beatrice 2 ; Fava Ludovico 2 ; Guglielmo, Simone 2
; Fascina Mariateresa 2 ; Grazioli, Marco 2 ; Alvisi Gualtiero 2 ; Vanuzzo Maria Cristina 3 ; Zupo Tiziano 3 ; Reginetta, Calandrin 3 ; Lisi Vittoria 3 ; Rossi, Lucia 3 ; Castagliuolo Ignazio 2 ; Merigliano Stefano 4
; Unwin H Juliette T 1
; Plebani, Mario 5 ; Padoan, Andrea 5 ; Brazzale, Alessandra R 6 ; Toppo Stefano 7 ; Ferguson, Neil M 1
; Donnelly, Christl A 8
; Crisanti, Andrea 9 1 Imperial College London, MRC Centre for Global Infectious Disease Analysis and the Abdul Latif Jameel Institute for Disease and Emergency Analytics, School of Public Health, London, UK (GRID:grid.7445.2) (ISNI:0000 0001 2113 8111)
2 University of Padova, Department of Molecular Medicine, Padova, Italy (GRID:grid.5608.b) (ISNI:0000 0004 1757 3470)
3 Azienda Ospedale Padova, Padova, Italy (GRID:grid.411474.3) (ISNI:0000 0004 1760 2630)
4 University of Padova, Department of Surgery, Oncology and Gastroenterology, Padova, Italy (GRID:grid.5608.b) (ISNI:0000 0004 1757 3470)
5 University of Padova, Department of Medicine, Padova, Italy (GRID:grid.5608.b) (ISNI:0000 0004 1757 3470)
6 University of Padova, Department of Statistical Sciences, Padova, Italy (GRID:grid.5608.b) (ISNI:0000 0004 1757 3470)
7 University of Padova, Department of Molecular Medicine, Padova, Italy (GRID:grid.5608.b) (ISNI:0000 0004 1757 3470); University of Padova, CRIBI Biotech Centre, Padova, Italy (GRID:grid.5608.b) (ISNI:0000 0004 1757 3470)
8 Imperial College London, MRC Centre for Global Infectious Disease Analysis and the Abdul Latif Jameel Institute for Disease and Emergency Analytics, School of Public Health, London, UK (GRID:grid.7445.2) (ISNI:0000 0001 2113 8111); University of Oxford, Department of Statistics, Oxford, UK (GRID:grid.4991.5) (ISNI:0000 0004 1936 8948)
9 University of Padova, Department of Molecular Medicine, Padova, Italy (GRID:grid.5608.b) (ISNI:0000 0004 1757 3470); Azienda Ospedale Padova, Padova, Italy (GRID:grid.411474.3) (ISNI:0000 0004 1760 2630); Department of Life Science Imperial College London, Exhibition Road, London, UK (GRID:grid.7445.2) (ISNI:0000 0001 2113 8111)




